Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Revenue of Bicycle Therapeutics plc (BCYC)
Revenue in 2023 (TTM): $26.98 M
According to Bicycle Therapeutics plc's latest financial reports the company's current revenue (TTM) is $26.98 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Bicycle Therapeutics plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $26.98 M | $20.4 M | $-168,804,000 | $-179,207,000 | $-180,664,000 |
| 2022 | $14.46 M | $10.78 M | $-110,897,000 | $-114,241,000 | $-112,717,000 |
| 2021 | $11.7 M | $-33,183,000 | $-65,498,000 | $-68,482,000 | $-66,819,000 |
| 2020 | $10.39 M | $-22,759,000 | $-51,277,000 | $-51,734,000 | $-51,010,000 |
| 2019 | $13.8 M | $-11,739,000 | $-26,299,000 | $-30,862,000 | $-30,608,000 |
| 2018 | $7.14 M | $-13,625,000 | $-21,034,000 | $-22,242,000 | $-21,846,000 |
| 2017 | $2.06 M | $-9,806,000 | $-15,881,000 | $-16,282,000 | $-16,259,000 |
| 2016 | $ | $-269,289 | $-13,224,120 | $-13,531,305 | $-13,510,360 |